title: What accounts for the higher clinical efficacy of intracoronary abciximab?
authors.affiliation: Division of Cardiology, "Magna Graecia" University of Catanzaro, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: De Rosa
authors.forename: Gianluca
authors.initials: G
authors.lastname: Caiazzo
authors.forename: Daniele
authors.initials: D
authors.lastname: Torella
authors.forename: Ciro
authors.initials: C
authors.lastname: Indolfi
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000401:mortality*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors
keywords: Abciximab; Acute coronary syndrome; Intracoronary